Watson, Orchid Defenses Live In Generic Azilect Row

Law360, New York (March 7, 2011, 5:20 PM EST) -- A New Jersey federal judge on Thursday refused to toss Watson Laboratories Inc. and Orchid Chemicals & Pharmaceuticals Ltd.'s inequitable conduct defenses in Teva Pharmaceutical Industries Ltd.'s suit over efforts to make a generic version of Parkinson's disease drug Azilect.

Judge Jose L. Linares of the U.S. District Court for the District of New Jersey denied Teva's motion to dismiss the defendants' four counterclaims and affirmative defenses alleging U.S. Patent Number 5,453,446 was unenforceable because the plaintiff intentionally misled the examiner and withheld several material prior...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.